

PBP1510 (Ulenistamab)

World's first targeted antibody therapy for **pancreatic cancer** with blockbuster potential

FDA Fast Track Designation

Triple orphan drug designation by FDA, EMA and MFDS

Overview


Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinoma up-regulated factor (**PAUF**) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer. It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells and tumor microenvironment TME.

Indication Pancreatic cancer, Ovarian cancer


Development Stage Phase 1/2a Clinical Trial in Europe and U.S.

What is PAUF

- Pancreatic Adenocarcinoma Up-regulated Factor
- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma (PDAC).
- PAUF over-expression is seen in other cancers including ovarian cancer, and in placenta.



Kim et al, Front Pharmacol. 2022 May 6;13:890614
Kim et al, Cancer Sci. 2009, 100(5): 828



The Cancer Genome Atlas (TCGA) genomic database

Reducing PAUF may improve survival of pancreatic cancer patients

MOA of PAUF Pathogenesis

PAUF promotes cancer progression and metastasis via multiple pathways

